Predictors of Response to Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2 (HER2)–Positive Breast Cancer and Pathological Evaluation of HER2 Heterogeneity

Puntos clave

• Tumor response to neoadjuvant therapy significantly varies among patients, highlighting the complexity of treatment outcomes.
• Key evidence includes variation in HER2 expression levels found in pathology reports, with implications for therapeutic strategies.
• Analysis of pathological evaluation reveals HER2 heterogeneity is a critical factor influencing treatment response.
• Findings suggest a need for personalized approaches in managing HER2-positive breast cancer, as existing treatments may not be universally effective.